Changchun High-Tech Industry (000661.SZ): GenSci's application for registering clinical trials for the production of 145 domestically produced drugs has been approved.
Changchun High-tech (000661.SZ) announcement, the company's subsidiary - Changchun GenSci Pharmaceutical Co., Ltd. (referred to as "GenSci Pharmaceuticals") has received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration. The domestic production drug registration clinical trial application for GenSci 145 tablets has been approved. GenSci 145 tablets is a new type of mutated selective PI3K inhibitor developed by GenSci Pharmaceuticals, which is classified as a first-class innovative chemical drug and is intended for the treatment of locally advanced or metastatic solid tumors with PIK3CA mutations.
Changchun High-Tech Industry (000661.SZ) announcement, the company's subsidiary - Changchun JinSai Pharmaceutical Co., Ltd. (referred to as "JinSai Pharmaceutical") has received the "Drug Clinical Trial Approval Notification" issued by the National Medical Products Administration. JinSai Pharmaceutical's domestic production drug GenSci145 tablets registration clinical trial application has been approved. GenSci145 tablets is a new type of selective PI3K inhibitor developed by JinSai Pharmaceutical, belonging to Class 1 innovative chemical drugs, intended for the treatment of locally advanced or metastatic solid tumors carrying PIK3CA mutations.
Related Articles

Software crashed together? Roblox (RBLX.US): It has an ecological closed-loop, Genie can't break.

Industrial: Hong Kong stock market sentiment index has reached the bottom area.

"The 'Chinese Choice' for Global SiC Core Customers: Why TIANYU SEMI (02658)?"
Software crashed together? Roblox (RBLX.US): It has an ecological closed-loop, Genie can't break.

Industrial: Hong Kong stock market sentiment index has reached the bottom area.

"The 'Chinese Choice' for Global SiC Core Customers: Why TIANYU SEMI (02658)?"

RECOMMEND

Nine Companies With Market Value Over RMB 100 Billion Awaiting, Hong Kong IPO Boom Continues Into 2026
07/02/2026

Hong Kong IPO Cornerstone Investments Surge: HKD 18.52 Billion In First Month, Up More Than 13 Times Year‑On‑Year
07/02/2026

Over 400 Companies Lined Up For Hong Kong IPOs; HKEX Says Market Can Absorb
07/02/2026


